These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 31555523)

  • 1. Sensitive molecular testing methods can demonstrate NSCLC driver mutations in malignant pleural effusion despite non-malignant cytology.
    Steinfort DP; Kranz S; Dowers A; Leas L; Dimitriadis V; Pham K; Hsu A; Bozinovski S; Irving LB; Loveland P; Christie M
    Transl Lung Cancer Res; 2019 Aug; 8(4):513-518. PubMed ID: 31555523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved detection of EGFR mutations in the tumor cells enriched from the malignant pleural effusion of non-small cell lung cancer patient.
    Wang Y; Liu Z; Yin H; Hu J; Zhong S; Chen W; Zhao J
    Gene; 2018 Feb; 644():87-92. PubMed ID: 29097164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of PNA clamping and direct sequencing for detecting KRAS mutations in matched tumour tissue, cell block, pleural effusion and serum from patients with malignant pleural effusion.
    Kang JY; Park CK; Yeo CD; Lee HY; Rhee CK; Kim SJ; Kim SC; Kim YK; Park MS; Yim HW
    Respirology; 2015 Jan; 20(1):138-46. PubMed ID: 25302858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Profiling of Malignant Pleural Effusion in Metastatic Non-Small-Cell Lung Carcinoma. The Effect of Preanalytical Factors.
    Carter J; Miller JA; Feller-Kopman D; Ettinger D; Sidransky D; Maleki Z
    Ann Am Thorac Soc; 2017 Jul; 14(7):1169-1176. PubMed ID: 28557526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytological-negative pleural effusion can be an alternative liquid biopsy media for detection of EGFR mutation in NSCLC patients.
    Song Z; Wang W; Li M; Liu J; Zhang Y
    Lung Cancer; 2019 Oct; 136():23-29. PubMed ID: 31421258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection and comparison of EGFR mutations in matched tumor tissues, cell blocks, pleural effusions, and sera from patients with NSCLC with malignant pleural effusion, by PNA clamping and direct sequencing.
    Yeo CD; Kim JW; Kim KH; Ha JH; Rhee CK; Kim SJ; Kim YK; Park CK; Lee SH; Park MS; Yim HW
    Lung Cancer; 2013 Aug; 81(2):207-12. PubMed ID: 23726527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Malignant pleural effusion cell blocks are substitutes for tissue in EML4-ALK rearrangement detection in patients with advanced non-small-cell lung cancer.
    Zhong J; Li X; Bai H; Zhao J; Wang Z; Duan J; An T; Wu M; Wang Y; Wang S; Wang J
    Cytopathology; 2016 Dec; 27(6):433-443. PubMed ID: 27060609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Yield of Malignant Pleural Effusion for Detection of Oncogenic Driver Mutations in Lung Adenocarcinoma.
    DeMaio A; Clarke JM; Dash R; Sebastian S; Wahidi MM; Shofer SL; Cheng GZ; Li X; Wang X; Mahmood K
    J Bronchology Interv Pulmonol; 2019 Apr; 26(2):96-101. PubMed ID: 30048416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell block samples from malignant pleural effusion might be valid alternative samples for anaplastic lymphoma kinase detection in patients with advanced non-small-cell lung cancer.
    Zhou J; Yao H; Zhao J; Zhang S; You Q; Sun K; Zou Y; Zhou C; Zhou J
    Histopathology; 2015 Jun; 66(7):949-54. PubMed ID: 25257756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of PANAMutyper and PNAClamp for Detecting KRAS Mutations from Patients With Malignant Pleural Effusion.
    Choi SY; Kim HW; Jeon SH; Kim BN; Kang N; Yeo CD; Park CK; Kim YK; Lee YH; Lee KY; Lee SH; Park JY; Park MS; Yim HW; Kim SJ
    In Vivo; 2019; 33(3):945-954. PubMed ID: 31028221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytology-Based Specimen Triage for Epidermal Growth Factor Receptor Mutation Testing of Malignant Pleural Effusions in Non-Small Cell Lung Cancer.
    Chiang CL; Shen CI; Huang HC; Chang HJ; Huang YT; Chiu CH
    Front Oncol; 2022; 12():810124. PubMed ID: 35141163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detecting EGFR mutations and ALK/ROS1 rearrangements in non-small cell lung cancer using malignant pleural effusion samples.
    Yao Y; Peng M; Shen Q; Hu Q; Gong H; Li Q; Zheng Z; Xu B; Li Y; Dong Y
    Thorac Cancer; 2019 Feb; 10(2):193-202. PubMed ID: 30565433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer.
    Tsai TH; Su KY; Wu SG; Chang YL; Luo SC; Jan IS; Yu CJ; Yu SL; Shih JY; Yang PC
    Eur Respir J; 2012 Mar; 39(3):677-84. PubMed ID: 21719485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurement and immunophenotyping of pleural fluid EpCAM-positive cells and clusters for the management of non-small cell lung cancer patients.
    Thompson JC; Fan R; Black T; Yu GH; Savitch SL; Chien A; Yee SS; Sen M; Hwang WT; Katz SI; Feldman M; Vachani A; Carpenter EL
    Lung Cancer; 2019 Jan; 127():25-33. PubMed ID: 30642547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next generation sequencing-based molecular profiling of lung adenocarcinoma using pleural effusion specimens.
    Liu L; Shao D; Deng Q; Tang H; Wang J; Liu J; Guo F; Lin Y; Peng Z; Mao M; Kristiansen K; Ye M; He J
    J Thorac Dis; 2018 May; 10(5):2631-2637. PubMed ID: 29997924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the SuperARMS and ARMS for detecting EGFR mutations in liquid-based cytology specimens from NSCLC patients.
    Wu W; Cao Z; Zhang W; Zhang L; Hou L; Wu C
    Diagn Pathol; 2020 Jan; 15(1):9. PubMed ID: 32005253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can we improve the cytologic examination of malignant pleural effusions using molecular analysis?
    Brock MV; Hooker CM; Yung R; Guo M; Han Y; Ames SE; Chang D; Yang SC; Mason D; Sussman M; Baylin SB; Herman JG
    Ann Thorac Surg; 2005 Oct; 80(4):1241-7. PubMed ID: 16181847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pleural fluid tumour markers in malignant pleural effusion with inconclusive cytologic results.
    Antonangelo L; Sales RK; Corá AP; Acencio MM; Teixeira LR; Vargas FS
    Curr Oncol; 2015 Oct; 22(5):e336-41. PubMed ID: 26628873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection and Significance of Cell-Free DNA Mutation in Pleural Effusion in Patients with Advanced NSCLC.
    Qiao M; Li D; He Y; Zhang C; Chi H; Li X; Cui Q; Li S; Jiao Y; Wei Y
    Emerg Med Int; 2022; 2022():3112281. PubMed ID: 35721255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-throughput screening of rare metabolically active tumor cells in pleural effusion and peripheral blood of lung cancer patients.
    Tang Y; Wang Z; Li Z; Kim J; Deng Y; Li Y; Heath JR; Wei W; Lu S; Shi Q
    Proc Natl Acad Sci U S A; 2017 Mar; 114(10):2544-2549. PubMed ID: 28223509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.